Raising the Bar for Atopic Dermatitis Treatment

Atopic dermatitis (AD) is entering a new phase of therapeutic innovation in which the goal is increasingly clear or almost-clear skin, little to no itch, and meaningful improvement in patients’ daily lives.

Our current targeted systemic therapies have transformed care, yet not every patient achieves those higher benchmarks. That gap is helping drive the next generation of development. Numerous investigational biologics are now being explored, including bispecific and trispecific agents designed to address multiple pathways simultaneously. Strategies combining IL-13 inhibition with targets such as IL-17A/F, the IL-31 receptor, and thymic stromal lymphopoietin (TSLP) may offer opportunities to push efficacy beyond what can be achieved by targeting a single pathway. Other approaches, including therapies aimed at enhancing regulatory T-cell activity, represent entirely different ways of potentially controlling inflammation and reducing disease flares.

Another important emerging area is our understanding of AD as more than a skin disease. In children, chronic systemic inflammation may be one contributor to impaired growth. In adults, we are only beginning to determine whether AD carries cardiovascular or cardiometabolic consequences similar to those increasingly recognized in psoriasis. We may soon learn whether modifying metabolic health through therapies such as GLP-1 receptor agonists can ultimately affect AD outcomes or response to targeted treatment.

Pediatric innovation is accelerating as well, with expanding studies of established and newer therapies across younger age groups. That growing evidence base should further refine how early and how effectively we intervene.

The articles in this issue highlight several important pieces of this evolving picture: advances in topical therapy, emerging data on pediatric growth with dupilumab, and the growing value of patient-reported outcomes. It is a very exciting time in atopic dermatitis. As we continue to push the boundaries with innovation, our treatment capabilities are transforming what is possible for patients.

Christopher Bunick, MD
Guest Medical Editor